Trial Profile
A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2019
Price :
$35
*
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
- 13 Dec 2019 Results assessing the immunogenicity and tolerability in adults published in the Vaccine
- 12 Oct 2017 Status changed from active, no longer recruiting to completed.
- 15 Sep 2017 Planned End Date changed from 31 Aug 2017 to 19 Sep 2017.